10/20/2014


CYTORI THERAPEUTICS CONTACT

Tiago Girao

(858) 458-0900

ir@cytori.com

Investor Note:  Cytori Patents Automated Tissue Processing Device in Japan and Treatments for Wound Healing In China

Dear Investors:

Cytori announced today that it recently received patents in Japan and China in two of the Company's key areas of focus:  tissue processing devices and adipose-derived regenerative cell (ADRCTM) therapy for burn injury. 

Japanese Patent No. 5,604,397 covers automated devices for processing adipose tissue in a closed system to obtain ADRCs.  The '397 Patent augments Cytori's existing Japanese patents, including several tissue processing device patents.  The '397 Patent highlights key features that set Cytori's devices apart from competitor products, including a processor that controls the various steps of tissue digestion and cell concentration, and an optical sensor that monitors tissue processing.  These features are present in Cytori's current Celution® line and in Cytori's next generation device, and advantageously minimize user input and enable high reproducibility of tissue processing.  The '397 Patent thus reinforces Cytori's market-leading position in Japan.  Cytori now has 11 issued patents in Japan.

Cytori was also recently awarded Chinese Patent No. 201110116176.X, that covers the use of ADRCs for the promotion of re-epithelialization and neodermis formation at a wound site.  Wound healing, and in particular healing of thermal burns, is a top corporate priority of Cytori. Cytori was recently awarded a multi-million dollar contract option from the Biomedical Advanced Research and Development Authority (BARDA) to fund studies of ADRC therapy for burn injury.  Cytori also continues to study ADRCs for the treatment of non-burn wounds, including non-healing ulcers.  The '176.X Patent specifically claims the use of ADRCs for treatment of traumatic wounds, burns, and ischemic ulcer wounds and adds to Cytori's worldwide patent protection of wound healing, which includes issued patents in the US, Europe, Japan, Hong Kong, Korea and India.  The issuance of '176.X Patent reinforces Cytori's commitment to commercializing Cytori's cell therapy for target indications in Asia-Pacific in collaboration with its partner, Lorem Vascular. 

Cytori now owns over 75 issued patents and over 45 pending applications worldwide. 


###

distributed by